IL-1拮抗薬の下垂体機能に及ぼす影響の評価
Fadime Aktas Koc1, Baris Sariakcali2, Ali Sahin3
1Department of Internal Medicine, Sivas Numune Hospital, Sivas, 58140, Türkiye, saglik.gov.tr.
International journal of endocrinology
|January 14, 2026
まとめ
インターロイキン-1(IL-1)阻害薬は、家族性地中海熱(FMF)患者の下垂体または副腎機能不全を引き起こさなかった。IL-1拮抗薬の下垂体機能への影響を完全に理解するには、さらなる研究が必要である。
科学分野:
- 内分泌学; リウマチ学; 遺伝学
背景:
- 家族性地中海熱(FMF)は、MEFV遺伝子変異によって引き起こされる自己炎症性疾患であり、IL-1β分泌と炎症の調節不全につながる。; IL-1阻害薬はFMFの治療法として登場しているが、内分泌機能への影響を調査する必要がある。
研究 の 目的:
- FMF患者におけるIL-1阻害薬の下垂体機能への影響を評価する。; IL-1阻害薬投与中のFMF患者とコルヒチン単独投与中の患者の下垂体ホルモンレベルを比較する。
主な方法:
- シヴァス・ジュムフリイェット大学病院で比較研究を実施した。; IL-1阻害薬を6ヶ月以上使用しているFMF患者とコルヒチンを投与されている対照群で、下垂体および内分泌ホルモンレベルを測定した。; 除外基準には、ステロイド使用、癌、血液透析が含まれた。コルチゾール欠乏症に対してSynacthenテストを実施した。
主要な成果:
- TSH、ACTH、コルチゾール、LH、エストラジオール、IGF-1、PRLレベルに群間差は認められなかった。FSHおよびGHレベルはコルヒチン単独群で高かった。総テストステロンレベルはIL-1阻害薬群で高かった。
結論:
- IL-1阻害薬は、FMF患者における有意な副腎または下垂体機能不全を引き起こさなかった。; IL-1はホルモン分泌に影響を与えるが、観察されたホルモン差の臨床的意義については、さらなる調査が必要である。
関連する概念動画
Hypothalamic-Pituitary Axis
65.4K
The response to stress—be it physical or psychological, acute or chronic—involves activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis is part of the neuroendocrine system because it involves both neuronal and hormonal communication. Its function is to regulate homeostatic systems—metabolic, cardiovascular, and immune—providing the necessary means to respond to a stressor.
65.4K
Hormones of the Pituitary Gland
9.4K
The small, pea-sized pituitary gland is located at the base of the brain. It is crucial in regulating various bodily functions, from growth to reproduction. The gland is divided into the anterior lobe and the posterior lobe. The secretory cell clusters in the pars distalis of the anterior pituitary lobe are controlled by hypothalamic regulators and synthesize six primary hormones.
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
9.4K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
457
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
457
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.4K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
438
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
438


